Parameter | |
---|---|
Age | median 61.6 years (range 36.9–91.4) |
Gender | 72% male (n = 134) 28% female (n = 53) |
Histology | 100% squamous cell carcinoma |
Oropharyngeal subsite | 52% tonsil (n = 97) 40% base of tongue (n = 75) 5% vallecula (n = 9) 2% soft palate (n = 4) 1% posterior wall (n = 2) |
T stage (UICC 7th edition) | 12% T1 (n = 22) 31% T2 (n = 59) 19% T3 (n = 36) 33% T4 (n = 61) 5% not available/recurrent disease (n = 9) |
N stage (UICC 7th edition) | 16% N0 (n = 30) 12% N1 (n = 22) 4% N2a (n = 7) 32% N2b (n = 60) 29% N2c (n = 55) 4% N3 (n = 7) 3% not available/recurrent disease (n = 6) |
UICC Stage (7th edition) | 8% Stage II (n = 15) 19% Stage III (n = 35) 67% Stage IVA (n = 122) 4% Stage IVB (n = 7) 2% Recurrent disease (n = 3) |
ECOG performance score | 80% ECOG 0 (n = 149) 15% ECOG 1 (n = 28) 5% ECOG 2 (n = 9) |
Tumor volume (combined nodal and primary volume); n = events (any recurrence) | median 40 cm3 (range 3–216 cm3); overall 52 events subgroup 1–15 cm3: 14% (n = 26); 3 events subgroup 15–70 cm3: 60% (n = 112); 28 events subgroup 70–130 cm3: 23% (n = 43); 17 events subgroup >130 cm3: 3% (n = 6); 4 events |
Smoking status | active = 62% (n = 116) stopped =25% (n = 46) never smoked = 13% (n = 25) |
NLR | median 3.33 (range 0.91–33.71) |
IMRT dose prescription | median 69.6 Gy (66–72 Gy) single dose 2–2.11 Gy |
Concomitant systemic therapy | 42% cisplatin weekly (n = 78) 47% reduced number of cisplatin cycles (n = 87) 7% cetuximab (n = 14) 4% no systemic therapy (n = 7) |
Induction chemotherapy | 8% of patients (n = 15) |
Follow-up | median 61.2 months (range 1.7–169) |